Vivos Therapeutics Stock Performance
| VVOS Stock | USD 1.50 0.02 1.32% |
The entity has a beta of 1.34, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Vivos Therapeutics will likely underperform. At this point, Vivos Therapeutics has a negative expected return of -0.6%. Please make sure to validate Vivos Therapeutics' potential upside and day median price , to decide if Vivos Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Vivos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:25 | Last Split Date 2023-10-27 |
1 | HC Wainwright Co. Initiates Coverage of Vivos Therapeutics with Buy Recommendation - Nasdaq | 11/17/2025 |
2 | Vivos Therapeutics, Inc. Q3 2025 Earnings Call Transcript | 11/21/2025 |
3 | Ascendiant Capital Maintains Vivos Therapeutics Buy Recommendation - Nasdaq | 12/03/2025 |
4 | Vivos Therapeutics to discuss strategy in Water Tower fireside chat - Stock Titan | 12/15/2025 |
5 | Is Vivos Therapeutics Inc. stock a safe buy before earnings - July 2025 EndofMonth Long-Term Safe Return Strategies - | 12/19/2025 |
6 | Vivos Therapeutics Upgraded to Buy Heres What You Should Know | 01/05/2026 |
7 | Vivos Therapeutics Announces Exercise of Warrants for 4.64 Million Gross Proceeds | 01/16/2026 |
8 | Vivos Therapeutics Announces Closing of Exercise of Warrants for 4.64 Million Gross Proceeds | 01/20/2026 |
9 | Acquisition by Bradford Amman of 100000 shares of Vivos Therapeutics at 7.5 subject to Rule 16b-3 | 01/28/2026 |
10 | Vivos Therapeutics, Inc. Short Interest Update | 02/03/2026 |
| Begin Period Cash Flow | 1.6 M | |
| Total Cashflows From Investing Activities | -568 K |
Vivos Therapeutics Relative Risk vs. Return Landscape
If you would invest 232.00 in Vivos Therapeutics on November 6, 2025 and sell it today you would lose (82.00) from holding Vivos Therapeutics or give up 35.34% of portfolio value over 90 days. Vivos Therapeutics is currently does not generate positive expected returns and assumes 4.9673% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Vivos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vivos Therapeutics Target Price Odds to finish over Current Price
The tendency of Vivos Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.50 | 90 days | 1.50 | close to 99 |
Based on a normal probability distribution, the odds of Vivos Therapeutics to move above the current price in 90 days from now is close to 99 (This Vivos Therapeutics probability density function shows the probability of Vivos Stock to fall within a particular range of prices over 90 days) .
Vivos Therapeutics Price Density |
| Price |
Predictive Modules for Vivos Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Vivos Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Vivos Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Vivos Therapeutics is not an exception. The market had few large corrections towards the Vivos Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Vivos Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Vivos Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.79 | |
β | Beta against Dow Jones | 1.34 | |
σ | Overall volatility | 0.27 | |
Ir | Information ratio | -0.16 |
Vivos Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Vivos Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Vivos Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Vivos Therapeutics generated a negative expected return over the last 90 days | |
| Vivos Therapeutics may become a speculative penny stock | |
| Vivos Therapeutics has high historical volatility and very poor performance | |
| Vivos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 15.03 M. Net Loss for the year was (11.14 M) with profit before overhead, payroll, taxes, and interest of 9.65 M. | |
| Vivos Therapeutics currently holds about 17.83 M in cash with (12.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77. | |
| Vivos Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 23.0% of the company outstanding shares are owned by insiders | |
| Latest headline from thelincolnianonline.com: Vivos Therapeutics, Inc. Short Interest Update |
Vivos Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Vivos Stock often depends not only on the future outlook of the current and potential Vivos Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vivos Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5 M | |
| Cash And Short Term Investments | 6.3 M |
Vivos Therapeutics Fundamentals Growth
Vivos Stock prices reflect investors' perceptions of the future prospects and financial health of Vivos Therapeutics, and Vivos Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vivos Stock performance.
| Return On Equity | -3.35 | ||||
| Return On Asset | -0.5 | ||||
| Profit Margin | (0.99) % | ||||
| Operating Margin | (0.70) % | ||||
| Current Valuation | 27.74 M | ||||
| Shares Outstanding | 11.42 M | ||||
| Price To Book | 6.86 X | ||||
| Price To Sales | 1.00 X | ||||
| Revenue | 15.03 M | ||||
| Gross Profit | 9.65 M | ||||
| EBITDA | (10.55 M) | ||||
| Net Income | (11.14 M) | ||||
| Cash And Equivalents | 17.83 M | ||||
| Cash Per Share | 0.77 X | ||||
| Total Debt | 1.51 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 3.15 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | (12.69 M) | ||||
| Earnings Per Share | (1.77) X | ||||
| Market Capitalization | 17.36 M | ||||
| Total Asset | 15.28 M | ||||
| Retained Earnings | (104.19 M) | ||||
| Working Capital | 2.5 M | ||||
About Vivos Therapeutics Performance
Assessing Vivos Therapeutics' fundamental ratios provides investors with valuable insights into Vivos Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Vivos Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 31.67 | 28.15 | |
| Return On Tangible Assets | (0.83) | (0.87) | |
| Return On Capital Employed | (1.25) | (1.31) | |
| Return On Assets | (0.84) | (0.88) | |
| Return On Equity | (1.61) | (1.69) |
Things to note about Vivos Therapeutics performance evaluation
Checking the ongoing alerts about Vivos Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vivos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vivos Therapeutics generated a negative expected return over the last 90 days | |
| Vivos Therapeutics may become a speculative penny stock | |
| Vivos Therapeutics has high historical volatility and very poor performance | |
| Vivos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 15.03 M. Net Loss for the year was (11.14 M) with profit before overhead, payroll, taxes, and interest of 9.65 M. | |
| Vivos Therapeutics currently holds about 17.83 M in cash with (12.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77. | |
| Vivos Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 23.0% of the company outstanding shares are owned by insiders | |
| Latest headline from thelincolnianonline.com: Vivos Therapeutics, Inc. Short Interest Update |
- Analyzing Vivos Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vivos Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Vivos Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vivos Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vivos Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vivos Therapeutics' stock. These opinions can provide insight into Vivos Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.